Clonal hematopoiesis and cytopenias following CAR19 therapy.

Clonal hematopoiesis commonly expands after CD19-directed CAR T therapy, and is linked to impaired immune reconstitution and treatment-related myeloid malignancy in treated lymphoma patients.

• Why it matters: CAR19 therapy improves survival but is limited by prolonged cytopenias, infections, and secondary hematologic malignancies, with unclear mechanisms driving these complications.
• What they did: Patients receiving CAR19 were compared with propensity-matched autoHCT-treated controls, including bone marrow and single-cell DNA analyses to characterize clonal cytopenias, interferon-mediated inflammation, and CH clone dynamics.
• The result: Post-CAR treatment-related myeloid malignancy was molecularly and clinically comparable to post-autoHCT tMN, and single-cell data showed mostly independent CH clones with frequent CAR integration into CH-mutant T cells that may support expansion and persistence.

AI summary of the abstract · may contain errors · not medical advice · read the paper.